# Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy

> **NCT01361412** · PHASE2 · COMPLETED · sponsor: **Circassia Limited** · enrollment: 20 (estimated)

## Conditions studied

- Ragweed Allergy

## Interventions

- **BIOLOGICAL:** ToleroMune Ragweed
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01361412
- **Lead sponsor:** Circassia Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2011-10-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01361412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01361412, "Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT01361412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*